Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

Summary

This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.

Timeline

Start

2018-11-27

Primary completion

2019-08-29

Completion

2019-08-29

Publications

• Agarwal G, Sangwan K. FDA-Approved Radiopharmaceuticals in Oncologic PET Imaging: Current Status and Clinical Impact. Am J Clin Oncol. 2026 Mar 4. doi: 10.1097/COC.0000000000001314. Online ahead of print.

Drugs

Indications